Definition
This entry describes the molecular biological aspects of HIV-2 and how they contrast with that of HIV-1.
Introduction
Since the first identification and cloning of the second human immunodeficiency virus HIV-2 (History of the AIDS epidemic, Epidemiology of HIV-2 infection in Europe, Recombinant forms of HIV-2, The epidemiology of HIV-2 infection in West Africa, The phylogeography of HIV-2 infection in West Africa), it has been clear from an abundance of clinical studies that this is a much less pathogenic virus than HIV-1 (Dual HIV-1 and HIV-2 infection, HIV-2 diagnosis and viral load measurements) and that it has a number of genetic molecular and structural differences from HIV-1. In seeking to understand the more often (though not always) benign outcome of infection with HIV-2, many studies have focused on these differences in seeking an explanation for this and also for the potential insights which it might give to understanding the pathogenicity of HIV-1 and ways to...
References
Bennett EM, Lever AM, Allen JF. Human immunodeficiency virus type 2 Gag interacts specifically with PRP4, a serine-threonine kinase, and inhibits phosphorylation of splicing factor SF2. J Virol. 2004;78:11303–12.
Bolinger C, Boris-Lawrie K. Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome. Retrovirology. 2009;6:8.
Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog. 2006;2:e10.
Briggs JA, Krausslich HG. The molecular architecture of HIV. J Mol Biol. 2011;410:491–500.
Camacho RJ. Special aspects of the treatment of HIV-2-infected patients. Intervirology. 2012;55:179–83.
Choe H, Martin KA, Farzan M, Sodroski J, Gerard NP, Gerard C. Structural interactions between chemokine receptors, gp120 Env and CD4. Semin Immunol. 1998;10:249–57.
Fujita M, Otsuka M, Nomaguchi M, Adachi A. Multifaceted activity of HIV Vpr/Vpx proteins: the current view of their virological functions. Rev Med Virol. 2010;20:68–76.
Gallo SA, Reeves JD, Garg H, Foley B, Doms RW, Blumenthal R. Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology. 2006;3:90.
Garcia-Martinez LF, Mavankal G, Peters P, Wu-Baer F, Gaynor RB. Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2. J Mol Biol. 1995;254:350–63.
Garrett ED, Cullen BR. Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2. J Virol. 1992;66:4288–94.
Herschhorn A, Hizi A. Retroviral reverse transcriptases. Cell Mol Life Sci. 2010;67:2717–47.
Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. 2010;8:55–67.
Kjems J, Askjaer P. Rev protein and its cellular partners. Adv Pharmacol. 2000;48:251–98.
L’Hernault A, Weiss EU, Greatorex JS, Lever AM. HIV-2 genome dimerization is required for the correct processing of gag: a second-site reversion in matrix can restore both processes in dimerization-impaired mutant viruses. J Virol. 2012;86:5867–76.
Le Tortorec A, Willey S, Neil SJ. Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses. 2011;3:520–40.
Lever AM. HIV-1 RNA packaging. Adv Pharmacol. 2007;55:1–32.
Marcello A, Zoppe M, Giacca M. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life. 2001;51:175–81.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914–20.
Tomasselli AG, Hui JO, Sawyer TK, Staples DJ, Bannow C, Reardon IM, et al. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem. 1990;265:14675–83.
Weiss ER, Gottlinger H. The role of cellular factors in promoting HIV budding. J Mol Biol. 2011;410:525–33.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this entry
Cite this entry
Lever, A.M.L. (2013). Molecular Biology of HIV-2. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_43-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_43-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine